Related Experiment Video
Updated: Jun 13, 2026
09:32
A Next-generation Tissue Microarray (ngTMA) Protocol for Biomarker Studies
Published on: September 23, 2014
Tissue microarray for routine clinical breast biomarker analysis. The British Columbia Cancer Agency 2008 experience
Thomas A Thomson1, Chen Zhou, Kathy Ceballos
1Department of Laboratory Medicine, British Columbia Cancer Agency, 600 W 10th Ave., Vancouver, BC, Canada.
American Journal of Clinical Pathology
|May 18, 2010
Summary
Tissue microarrays offer a reliable and cost-effective method for analyzing key breast cancer biomarkers, including estrogen receptor, progesterone receptor, and HER2. This study reports on the initial year of clinical application of this technique.
Area of Science:
- Oncology
- Pathology
- Biomarker Analysis
Background:
- Estrogen receptor (ER), progesterone receptor (PR), and HER2 are critical biomarkers in breast cancer diagnostics and treatment.
- Immunohistochemistry (IHC) is a standard method for evaluating these biomarkers.
- Tissue microarrays (TMAs) offer a method for high-throughput biomarker analysis.
Purpose of the Study:
- To evaluate the clinical utility and initial results of implementing tissue microarrays for immunohistochemical analysis of breast cancer biomarkers.
- To assess the reliability and cost-effectiveness of TMAs in a clinical laboratory setting.
Main Methods:
- Implementation of tissue microarrays for routine clinical testing in 2008.
- Immunohistochemical analysis of estrogen receptor, progesterone receptor, and HER2 on tissue microarrays.
- Evaluation of the reliability and cost-effectiveness of the TMA method.
Main Results:
- The tissue microarray method for immunohistochemical analysis of breast biomarkers proved to be reliable.
- The implemented method was found to be cost-effective.
- Initial year of testing demonstrated successful clinical application.
Conclusions:
- Tissue microarrays provide a dependable and economical approach for the clinical immunohistochemical assessment of ER, PR, and HER2 in breast cancer.
- The adoption of TMAs in 2008 marked a significant advancement in our laboratory's diagnostic capabilities for breast cancer biomarkers.
